SBIR/STTR Research Award
Ultrasensitive detection of protein targets in plasma for early detection of cancer
Award amount
$321,869Program and phase
SBIR · Phase IAward year
2020Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Alamar Biosciences, Inc.
- Proposal award date
- 2020-07-01
- Contract end date
- 2021-06-30
- UEI
- ED4RPQ2UJ9G8
- Solicitation number
- PA19-272
- Topic code
- 102
Research abstract
PROJECT SUMMARY
Early detection of cancer is amongst the most important problems to address in biomedical
research because the earlier cancer is detected, the better chance of a cure or a successful
treatment. In contrast to the current approach of DNA liquid biopsy, we propose to develop an
ultra-sensitive immunoassay technology that enables protein liquid biopsy for early cancer
detection. By leveraging our insights in improving signal-to-background ratio, we have
developed a prototype immunoassay named NULISA, or NUcleic acid-Linked Immuno-
Sandwich Assay, that has achieved unprecedented level of detection sensitivity of any
commercially available immunoassays at ~20,000 molecules/mL (i.e. ~30 aM). In this proposal,
we aim to optimize the NULISA assay to further boost lower limit of detection and limit of
quantitation (LOD and LOQ) and test a few candidate markers for their potential in early cancer
detection. The specific aims of this Phase 1 SBIR proposal include: 1) Optimize single plex
NULISA for ultrasensitive detection of protein markers in plasma and demonstrate minimally 10-
fold better detection sensitivity over the most sensitive immunoassay on market; and 2)
Demonstrate initial proof of concept of NULISA for early cancer detection. At the end of this
project, we expect to have established a high performance NULISA assay and the feasibility of
novel markers for early cancer detection. The longer-term goal of the project is to develop
noninvasive single- and/or pan-cancer screen tests that could detect cancer much earlier for
more successful or curative treatment.PROJECT NARRATIVE
This project aims to develop a novel ultra-sensitive immunoassay technology that enables
protein liquid biopsy and demonstrates feasibility for early cancer detection. The longer-term
goal of the project is to develop noninvasive single- and/or pan-cancer screen tests that could
detect cancer much earlier for more successful or curative treatment.
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- MiREA, a mHealth intervention to Reduce Health Disparities by Improving Equitable Access to Mandated College Students with Problematic Alcohol and Marijuana Use
- Modex, a cloud-based, centralized health economic model marketplace to reduce costs and enhance equity in cancer
- Precision screening in self-collected samples to reduce cervical cancer disparities among Latinas
- Allogeneic cell and gene therapy for neuroendocrine tumors
- Nanoparticle formulation of Mediator kinase inhibitor for the treatment of peritoneal ovarian cancer